WHO Warns DRC Ebola Response Remains Critical in North Kivu

The fight against the Ebola outbreak in the Democratic Republic of Congo is far from over, according to the World Health Organization. Despite encouraging signs in certain areas, the agency warned that the situation remains critical, particularly in the eastern regions where transmission continues to spread among multiple distinct clusters.

Tedros Adhanom Ghebreyesus, the director-general of the WHO, emphasized during an online news conference that officials are racing to control the spread of the virus. He noted that the scale of the affected area makes it difficult to treat the situation as a single epidemic, describing it instead as a complex challenge involving many outbreaks in various locations.

Case Surge in Northern Provinces

According to reports from Al Jazeera English, the number of weekly cases in North Kivu province has doubled over the past two weeks. The figure rose from approximately 100 to more than 200, signaling a sharp increase in transmission. This surge contrasts with data from other parts of the country, where the trend is moving in a different direction.

In Ituri province, which served as the initial epicentre of the outbreak, transmission rates are reported to be declining. Similarly, South Kivu has not recorded any new cases since May. However, Tedros cautioned that these localized improvements do not negate the overall growth of the epidemic, which continues to claim lives across the seven affected provinces.

Challenges of Rare Viral Strain

The response to the outbreak has been complicated by the presence of the Bundibugyo strain of Ebola. This rare variant currently has no known cure, presenting significant hurdles for medical teams. While standard treatments for other forms of the virus are available, the specific characteristics of this strain require different therapeutic approaches and monitoring protocols.

Efforts to develop effective treatments and post-exposure prophylaxis are accelerating, according to WHO officials. Meg Doherty, the director of science, research, evidence, and quality for health, stated that more than 3,000 healthcare and front-line workers have been vaccinated. This proactive measure aims to protect those on the front lines while they work to contain the spread.

Vaccine Efficacy and Future Outlook

The vaccine currently in use, Ervebo by Merck, is licensed against the Zaire ebolavirus. However, its effectiveness against the Bundibugyo strain driving the current crisis remains uncertain. This uncertainty adds a layer of complexity to the vaccination strategy, as health officials must balance immediate protection with the need for data on long-term efficacy against this specific variant.

Since the declaration of the 17th Ebola outbreak in May, more than 7,200 cases and over 3,500 deaths have been reported across seven provinces. As the situation evolves, the focus remains on controlling transmission in North Kivu while continuing to monitor developments in other regions. The coming weeks will be crucial in determining whether the momentum for containment can be sustained.